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RESEARCH NOTE
Evaluation of Xpert MTB/RIF testing 
for rapid diagnosis of childhood pulmonary 
tuberculosis in children by Xpert MTB/RIF 
testing of stool samples in a low resource 
setting
Zahra Hasan1* , Sadia Shakoor1, Fehmina Arif2, Aisha Mehnaz2, Alnoor Akber1, Marium Haider2, Akbar Kanji1 
and Rumina Hasan1
Abstract 
Objective: Children with tuberculosis (TB) remain underdiagnosed due to difficulty in testing for Mycobacterium 
tuberculosis (MTB) infection. We evaluated the Xpert MTB/RIF assay for respiratory and stool testing in children for pul-
monary TB through a cross-sectional study at tertiary care facilities in Karachi, Pakistan. Fifty children aged 0–15 years 
screened by a modified Kenneth-Jones (KJ) score were included. Mycobacterial culture of respiratory samples was 
the microbiological standard against stool Xpert TB results. All positive TB cases were compared against a treatment 
response standard (TRS).
Results: Twelve study subjects were diagnosed by Xpert TB and nine by MTB culture. Compared with culture [gastric 
aspirates (GA)/sputum (spm)], stool Xpert TB had a sensitivity of 88.9% (95% CI 50.7–99.4) and a specificity of 95% 
(95% CI 81.8–99.1). Xpert TB stool versus GA/spm had sensitivity of 81.8% (95% CI 47.8–96.8) and specificity of 94.7% 
(95% CI 84.6–99.9). We found good agreement (kappa scores of >0.8) between stool Xpert, GA/spm Xpert and GA/
spm culture. Stool Xpert PPV and NPV against TRS was 100 and 82.1% respectively. Stool Xpert TB is a relatively easy 
option for diagnosis for pulmonary childhood TB in a high burden low-resource setting.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Pakistan ranks 5th amongst high tuberculosis (TB) bur-
den countries and 36% of its population comprises chil-
dren under 15  years. At least 1 million children fall ill 
with TB each year. Children represent about 11% of all TB 
cases [1]. The incidence of TB in Pakistan is 255/100,000 
in adults and 46/100,000 in children [1]. Under-diagnosis 
and under-reporting of TB occurs in children. Diagnosis 
is often based on clinical signs with algorithms of expo-
sure to TB and chest X-ray (CXR) and immunological 
reactivity [2, 3]. Microbiological confirmation of TB in 
young children is difficult due to the problems in obtain-
ing appropriate respiratory specimens; young children do 
not produce sputum and it is difficult to collect invasive 
specimens such as gastric aspirates (GA).
Xpert MTB/RIF assay (Cepheid Sunnyvale, USA) 
allows simultaneous detection of Mycobacterium tuber-
culosis (MTB) and rifampicin resistance, with a pooled 
sensitivity of 89% for pulmonary TB in adults [4]. In chil-
dren, the pooled sensitivities and specificities of Xpert for 
TB detection using respiratory specimens and GA com-
pared with culture, was 62–66 and 98%, respectively 
[5]. Nicol et al. describe the effectiveness of Xpert stool 
testing in children compared with induced sputum and 
GA with a sensitivity of overall 47%, with 80% in HIV 
infected and 33% in non-HIV infected children [6]. Here, 
Open Access
BMC Research Notes
*Correspondence:  zahra.hasan@aku.edu 
1 Department of Pathology and Laboratory Medicine, The Aga Khan 
University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan
Full list of author information is available at the end of the article
Page 2 of 6Hasan et al. BMC Res Notes  (2017) 10:473 
we investigated stool-based Xpert as alternate to respira-
tory samples from non-HIV children suspected of pul-
monary TB.
Main text
Methods
The study was conducted at Civil Hospital Karachi 
(CHK), Dow University of Health Sciences (DUHS), and 
The Aga Khan University Hospital (AKUH), Karachi, 
Pakistan (October 2014 to November 2015). CHK is a 
tertiary care public hospital with pediatric units includ-
ing, a TB clinic linked with the National Tuberculosis 
Control Program Pakistan (NTP). The AKUH-Pakistan 
is a tertiary care teaching hospital. This was a cross-sec-
tional study with convenience sampling method.
Children up to 15 years of age suspected to have pul-
monary tuberculosis were screened for the study based 
on clinical symptoms including, history of fever, cough, 
weight loss and abdominal distention. Subsequently, a 
physical exam and chest Xray were performed. Patients 
were further assessed according to the diagnostic algo-
rithm utilized by the Pakistan Pediatric Association 
which is based on the NTP case management deskguide 
[3]. This is a modified Kenneth-Jones (KJ) criteria (Addi-
tional file 1: Table S1) [2] and scores patients according 
to their ‘risk’ assessment  based on the presence of risk 
factors such as, contact with an adult TB patient, lack of 
BCG vaccination, the occurrence of measles infection, 
PCM grade III and immune compromise due to malig-
nancies or steroid treatment. We enrolled patients with 
a KJ score of ≥5 subject to informed consent. One res-
piratory and stool sample was collected per child. Gastric 
aspirates (GA) were collected early morning nasogas-
tric intubation following an overnight fast. GA samples 
were tested by Xpert TB and MTB culture and sensitivity 
(MTBCS). In patients who produced sputum (spm) years 
this specimen was utilized instead of GA for Xpert TB 
and MTBCS.
GA samples collected at CHK were transported to 
AKUH and processed within 24  h. GA samples were 
divided into two parts; one was neutralized with 4% 
sodium carbonate, digested-decontaminated with 
N-acetyl-L-cystine and 4% sodium hydroxide, cen-
trifuged at 3000  g to set up MTB culture using liquid 
mycobacterial growth indicator tube (MGIT) 960 sys-
tem (Becton–Dickinson, USA). Mycobacterial culture 
and drug susceptibility testing (DST) were performed 
as described previously [7]. The second part of the res-
piratory sample was diluted 2:1 in Xpert sample reagent, 
shaken vigorously, incubated at room temperature for 
15 min and added to the Xpert cartridge.
Stool was collected within 24 h of GA samples, stored 
at 2–8  °C, transported to AKUH and stored at −80  °C 
until processed as described previously [6]. Briefly, 0.15 g 
of thawed stool was placed in 2.4 mL phosphate buffered 
saline (PBS) and vortexed, left undisturbed for 20  min 
at room temperature before a 1  mL supernatant was 
removed, centrifuged at 3500 rpm for 15 min. The super-
natant was discarded and pellet re-suspended in 1  mL 
PBS, then diluted 2:1 in sample reagent and added to the 
Xpert cartridge. Xpert GA results were reported to phy-
sicians within 24 h of processing.
Study subjects were diagnosed with TB based on a 
positive microbiological test result (a positive MTB cul-
ture and/or positive Xpert MTB/RIF on gastric aspi-
rate). In addition, some were given empirical treatment 
based on the evaluation by the treating pediatrician. TB 
patients were treated according to the Pakistan Pediatric 
Association guidelines for TB; 2 months of isoniazid (H), 
rifampicin (R), pyrazinamide (Z) and ethambutol (E) fol-
lowed with 4 months HR. All patients were followed by 
regularly every 4–6 weeks and underwent history taking 
and physical examination. Children were evaluated for 
adherence to treatment response to treatment (resolution 
of symptoms, weight gain, radiographic improvement) 
and monitored for adverse reaction to medications. End 
of treatment follow up was conducted either in clinic or 
over the telephone for out of town study subjects.
Patient demographics, Xpert TB and MTBCS results 
were entered in MS Excel. Xpert stool and Xpert respira-
tory sample sensitivities were derived by comparing to 
respiratory culture. FDA Statistical guidance on report-
ing results from studies evaluating diagnostic tests was 
used to calculate sensitivity and specificity of the assay 
and positive and negative percent agreements (PPA, 
NPA) with kappa scores [8].
Response to empiric anti-tuberculous treatment (ATT) 
in children who tested negative for microbiological diag-
nosis (negative TB culture and negative Xpert) was con-
sidered as evidence for TB [9, 10]. We used this criterion 
as a Treatment Response Standard (TRS) to determine 
the positive predictive value (PPV) and negative predic-
tive value (NPV) and specificity of Xpert in stool. Data 
was analysed and parameters calculated in MS Excel. [8].
Results
A total of sixty-four children were assessed of which fifty 
were found to fit the study criteria with a KJ score of ≥5, 
(Fig. 1). Study subjects included 28 males and 22 females 
(Table  1 and Additional file  2: Table S2) and ages rang-
ing from 7 months to 15 years. The Median (Interquartile 
range) age of the children was 6.8 (9–2) years. Fifty-four 
percent (54%; n =  27) of child TB subjects had contact 
with an adult TB patient. Only 46% (n = 23) of children 
had a history of BCG vaccination based on parental recall 
and 30% (n =  15) had a BCG scar. Two children had a 
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history of measles in the 6 months preceding the present-
ing illness. Forty-six percent (n = 23) of the total group 
and 61% (n  =  14) of under 5  year olds suffered from 
protein calorie malnutrition (PCM) grade 3. Thirty per-
cent (n = 15) of the overall group and 39% (n = 9) of the 
under 5  year group were immune-compromised due to 
steroid treatment, immune-deficiencies or malignancies. 
Human immunodeficiency virus (HIV) testing was not 
performed in the study subjects.
In total 48 GA and 2 spm samples were collected. Stool 
samples were collected in 49 cases and could not be col-
lected in one case where the subject had expired. Paired 
respiratory (GA/spm) and Stool samples were avail-
able for 49 cases described in Additional file 2: Table S2. 
All MTB cultures were drug susceptible and similarly, 
rifampicin resistance was not detected in Xpert positive 
samples. Microbiological testing of GA samples showed 
11 positive cases by Xpert and 9 positive cases by MTBC. 
The 2 sputum samples were negative by both Xpert and 
MTBC. Stool Xpert testing revealed 10 positive cases. 
Table 1 shows results of Xpert GA and stool testing using 
Xpert and GA MTB culture amongst study subjects.
Overall, 12 children were diagnosed with TB based 
on microbiological tests and an additional 6 children 
were diagnosed clinically. All of the eighteen TB cases 
were prescribed empirical first-line ATT. One child died 
after 1 month of ATT due to an unrelated accident. The 
remaining 17 TB cases showed clinical improvement.
When compared with GA culture standard, Xpert in 
stool had a sensitivity of 88.9% (95% CI 50.7–99.4) and a 
specificity of 95% (95% CI 81.8–99.1), Table 2.
Xpert GA versus culture had sensitivity of 100% (95% 
CI 62.9–100) and specificity of 95% (95% CI 81.8–99.1). 
Xpert stool vs GA had sensitivity 81.8% (95% CI  47.8–
96.8) and specificity 94.7% (95% CI  80.9–99.1). There 
was very good agreement (kappa scores of >0.8) between 
stool Xpert and GA Xpert and GA culture.
Sensitivity, specificity, PPV, and NPV of GA and stool 
Xpert were also calculated with a treatment response 
standard (TRS). Xpert in stool had a sensitivity of 58.8% 
(95% CI 33.5–80.6), specificity of 100% (86.7–100), PPV 
of 100% (95% CI  65.5–100) and NPV of 82.1% (95% 
CI 65.9–91.9) against a TRS. Overall percent positive and 
negative agreements of stool Xpert with GA culture & 
GA Xpert and Cohen’s kappa is calculated and presented 
as part of Table 2.
Discussion
There is a high burden of largely underdiagnosed child-
hood TB in South Asian countries including, Pakistan 
[11]. There is a need for rapid, easy diagnostics for child 
TB in such settings. National guidelines for TB care in 
Pakistan recommend the use of Xpert as an initial test for 
diagnosis TB in children. However,  due the difficulty in 
obtaining suitable specimens for testing diagnosis of TB 
in children has generally been low [12].
Study subjects screened based on clinical 
history (n=64)
Subjects excluded with KJ score<5 (n=14) #Subjects recruited for microbiological tesng
based on KJ≥5 (n=50)
50 respiratory samples; GA n=48, sputum 
(n=2)
N=49 stool samples tested by TB Xpert *
Stool; TB Xpert pos (n=11); neg (n=38)
GA; MTBC pos (n=9); TB Xpert pos (n=11)
Sputum; MTBC, neg (n=2), TB Xpert neg 
(n=2)
Posive TB diagnosis; microbiology posive 
(n=12); empirical ATT (n=6)
Follow of response to treatment; 17 TB paents 
were noted to show clinical improvement**
Fig. 1 Outline of study. ‘#’ additional tests done for this study together with routine GA/sputum MTB culture were TB Xpert on GA/sputum and stool 
specimens of each study subject; asterisk one study subject expired prior to collection of stool sample; double asterisk end of treatment follow up 
was available for 17 cases only as one study subject expired
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Here, we show that Xpert testing of stool has compa-
rable performance and good agreement with Xpert GA 
testing in a cohort of children with high probability of 
pulmonary TB. Our data is in line with previous reports 
[6], including a recent systematic review of Xpert-based 
childhood TB diagnosis with pooled sensitivity of 62% for 
respiratory specimens (5).
We observed the sensitivity of stool Xpert to be 88.9% 
as compared with GA culture, 100% with GA Xpert and 
81.8% with GA Xpert. The stool Xpert sensitivity we 
observed was higher than that shown by Nicol et  al. in 
non-HIV children [6] and by Chipinduro et  al. in HIV 
and non-HIV children [13] possibly, due to the screening 
tool (modified KJ score) we used to recruit children with 
high likelihood of TB. However, the sensitivity of Xpert 
stool we observed was similar to that reported by Banada 
et  al. [14] who tested larger quantities of replicate stool 
samples from children with pediatric TB. A limitation of 
our study was that we were able to only collect one set 
of stool and GA samples. Marcy et al. showed that when 
additional respiratory samples such as, nasopharyngeal 
aspirates were taken together with stool Xpert the sen-
sitivity was increased by 10%, improving chances of TB 
diagnosis [15].
The NTP has installed more than 50 Xpert machines 
installed in selected tertiary, secondary care hospitals 
and specialized TB clinics. As stool is easily obtained we 
hope that this work can be extended to implementation 
in the NTP, allowing the described method to be imple-
mented in a decentralized setting. It would be most effec-
tive to combine stool Xpert with testing of additional 
respiratory samples (GA, NPA) by Xpert for the diagno-
sis of childhood TB as it is highly likely to improve yield 
of TB diagnosis. Overall, we show that stool Xpert testing 
can improve microbiological diagnosis and confirmation 
of TB in children at high risk for TB in the local setting.
Limitations
Due to the limited study budget the sample size of the 
study was relatively small. Also, we were only able to 
collect a single stool sample rather than successive daily 
samples. HIV testing was not performed on the study 
subjects.
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Additional files
Additional file 1: Table S1. Modified Kenneth Jones Score/ Pakistan 
Paediatrics Association scoring chart for diagnosis of TB in children. ‘0-2’ TB 
unlikely; ‘3-4’ Keep under observation for possible TB for 3 months; ‘5-6’ Tuber-
culosis possible (Investigations may justify therapy; ‘7’ or more TB probable and 
needs to be confirmed. ‘*’ Include children with malignancies (leukemias, 
lymphomas), immunodeficiencies, and immunosuppressive therapy such 
as chronic steroids more than 2 weeks. PCM Grade 3= Protein Calorie Mal-
nutrition grade 3 not improving after 4 weeks of adequate caloric intake. 
‘**’ Physical Examination Suggestive of TB: Pulmonary findings (unilateral 
wheeze, dullness), hepatosplenomegaly, ascites; Strongly suggestive of 
TB: Matted lymphadenopathy, abdominal mass, gibbus formation, chronic 
monoarthritis, CNS findings (bulging fontanelle, irritability, papilledema). 
‘†’ Radiological findings: Nonspecific: Ill-defined opacity/infiltrates; marked 
broncho-vascular marking. Suggestive of TB: Consolidation not respond-
ing to antibiotic therapy; paratracheal, tracheal, or mediastinal lymphad-
enopathy, miliary mottling.
Additional file 2: Table S2. Characteristics of Pediatric Study subjects 
enrolled for TB testing. Data was compiled as per information collected 
from Modified Kenneth Jones Score sheet (Additional file 1: Table S1). The 
presence of an identifier is, “1” and absence is, “0”; na, not available.
Table 2 Performance characteristics of Xpert in stool in comparison with culture and gastric aspirate Xpert standards
Sensitivity, specificity, 95% confidence intervals (CI), positive percent agreement (PPA), and negative percent agreement (NPA), and kappa scores were calculated in 
MS Excel
Test Reference standard Number of patients 
included in evalu-
ation
Sensitivity % (95% 
CI)
Specificity % (95% 
CI)
PPA (%) NPA (%) Kappa agreement 
(95% CI)
Stool Xpert GA culture 49 88.9 (50.7–99.4) 95 (81.8–99.1) 88.9 95 0.804 (0.592–1.00)
GA Xpert 49 100 (62.9–100) 95 (81.8–99.1) 100 95 0.875 (0.706–1.00)
GA Xpert Stool Xpert 49 81.8 (47.8–96.8) 97.4 (84.6–99.9) 81.8 97.3 0.818 (0.62–1.00)
Page 6 of 6Hasan et al. BMC Res Notes  (2017) 10:473 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Acknowledgements
We thank Dr. Farah Naz Qamar, The Aga Khan University, Pakistan, for her 
contribution and the Department of Pediatrics at Civil Hospital, Karachi for 
assistance with patient recruitment. Thanks to Dr. Sabira Tahseen, National TB 
Program Pakistan for her input on the paper.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Relevant data is provided in the Additional files 1 and 2.
Consent for publication
All authors have consented to publication of this manuscript.
Ethics approval and consent to participate
This study was approved by the Ethical Review Committee, The Aga Khan Uni-
versity (AKU) and Institutional Review Board, DUHS, Karachi. Written informed 
consent was taken from the parent/guardian of each study subject. In children 
aged 10–15 years an assent form was also completed.
Funding
This investigation received technical and financial support from the joint WHO 
Eastern Mediterranean Region (EMRO), and the WHO Special Programme for 
Research and Training in Tropical Diseases (TDR): “The EMRO/TDR Small Grants 
Scheme for Operational Research in Communicable Diseases”.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 7 April 2017   Accepted: 7 September 2017
References
 1. World Health Organization. Global tuberculosis report. Geneva: World 
Health Organization; 2016.
 2. Mehnaz A, Arif F. Applicability of scoring chart in the early detection of 
tuberculosis in children. J Coll Physicians Surg Pak. 2005;15(9):543–6.
 3. NTP. National guidelines for diagnosis and management of tuberculosis 
in children; 2007.
 4. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. 
Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resist-
ance in adults. Cochrane Database Syst Rev. 2014;1:CD009593.
 5. Detjen AK, DiNardo AR, Leyden J, Steingart KR, Menzies D, Schiller I, 
et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis 
in children: a systematic review and meta-analysis. Lancet Respir Med. 
2015;3(6):451–61.
 6. Nicol MP, Spiers K, Workman L, Isaacs W, Munro J, Black F, et al. Xpert MTB/
RIF testing of stool samples for the diagnosis of pulmonary tuberculosis 
in children. Clin Infect Dis. 2013;57(3):e18–21.
 7. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis. 
2000;31(5):1209–15.
 8. Adminstration FaD. Statistical guidance on reporting results from studies 
evaluating diagnostic tests; 2007.
 9. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of 
diagnostic approaches used in the diagnosis of childhood tuberculosis. 
Int J Tuberc Lung Dis. 2002;6(12):1038–45.
 10. Bergman NJ. A “treatment score” for primary and pulmonary tuberculosis. 
Cent Afr J Med. 1995;41(1):1–6.
 11. Shakoor S, Qamar FN, Mir F, Zaidi A, Hasan R. Are TB control programmes 
in South Asia ignoring children with disease? A situational analysis. Arch 
Dis Child. 2015;100(2):198–205.
 12. World Health Organization. Global tuberculosis report. Geneva: World 
Health Organization; 2015.
 13. Chipinduro M, Mateveke K, Makamure B, Ferrand RA, Gomo E. Stool 
Xpert(R) MTB/RIF test for the diagnosis of childhood pulmonary 
tuberculosis at primary clinics in Zimbabwe. Int J Tuberc Lung Dis. 
2017;21(2):161–6.
 14. Banada PP, Naidoo U, Deshpande S, Karim F, Flynn JL, O’Malley M, et al. A 
novel sample processing method for rapid detection of tuberculosis in 
the stool of pediatric patients using the Xpert MTB/RIF assay. PLoS ONE. 
2016;11(3):e0151980.
 15. Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, et al. Perfor-
mance of Xpert MTB/RIF and alternative specimen collection methods 
for the diagnosis of tuberculosis in HIV-infected children. Clin Infect Dis. 
2016;62(9):1161–8.
